Nail Psoriasis. Psoriasis, unspecified
Conditions
Interventions
Intervention 1: Intervention group: First Group (Tofacitinib): 5 mg oral tofacitinib tablets (brand name "Urositra," manufactured by Sobhan Darou Pharmaceutical Co., Iran) administered orally once eve
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Diagnosis of psoriatic arthritis based on CASPAR criteria Presence of nail involvement confirmed by rheumatologist and dermatologist History of using DMARDs for controlling psoriatic arthritis Age over 18 years Ability to provide written informed consent
Exclusion criteria
Exclusion criteria: History of hypersensitivity to the medications used in the study Presence of severe infections or concurrent malignancies Pregnancy or breastfeeding Concurrent presence of other rheumatologic diseases History of fungal or infectious nail diseases History of deep vein thrombosis (DVT) History of cardiovascular diseases Being a smoker Use of medications that may interfere with the study drugs Participation in other clinical trials within the past 30 days Presence of severe psychiatric disorders affecting compliance with the study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nail Psoriasis Severity Index (NAPSI) score. Timepoint: At baseline (week 0) and at weeks 8, and 12 after treatment initiation. Method of measurement: Researcher-Made Checklist. | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of treatment-related adverse events associated with tofacitinib or adalimumab in patients with psoriatic arthritis during the 12 weeks following treatment initiation. Timepoint: Baseline (prior to initiation of treatment), Week Week 8 after treatment initiation, and Week 12 (end of treatment period). Method of measurement: Researcher-Made Checklist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAliakbar Gorjipour
Ahvaz University of Medical Sciences
Outcome results
None listed